Early Cervical Cancer: Predictive Relevance of Preoperative 3-Tesla Multiparametric Magnetic Resonance Imaging
Table 1
Comparison of the distribution of clinical and pathologic characteristics of the 260 women in the cohort study stratified by MRI staging.
Clinical characteristics
MRI T0 (n=57)
MRI T1b (n=139)
MRI T2a (n=10)
MRI T2b (n=54)
P-value
Age(y)
47.6
49.5
47.9
52.1
0.207
Parity
2.1
2.2
1.9
2.3
0.773
Operative procedure
0.01
Open modified radical hysterectomy
2(3.5)
1(0.7)
0(0)
0(0)
Open radical hysterectomy
9(15.8)
47(33.8)
2(20.0)
25(46.3)
Laparoscopic modified radical hysterectomy
20(35.1)
9(6.5)
0(0)
1(1.9)
Laparoscopic radical hysterectomy
22(38.6)
77(55.4)
8(80.0)
28(51.9)
Laparoscopic radical trachelectomy
3(5.3)
3(2.2
0(0)
0(0)
Robotic radical hysterectomy
1(1.8)
1(0.7)
0(0)
0(0)
Robotic trachelectomy
0(0)
1(0.7)
0(0)
0(0)
Menopause
0.004
No
37(64.9)
79(56.8)
5(50)
21(38.9)
Yes
20(35.1))
60(43.2)
5(50)
33(61.1)
Cesarean section
0.101
No
54(94.7)
122(87.8)
7(70)
46(85.2)
Yes
3(5.3)
17(12.2)
3(30)
8(14.8)
History of at least one normal delivery
0.381
No
7(12.3)
18(12.9)
5(50)
8(14.8)
Yes
50(87.7)
121(87.1)
5(50)
46(85.2)
BMI
24.1
23.9
24.3
23.8
0.948
SCC Ag (ng/ml)
0.9
2.7
3.9
10.1
<0.0001
CEA(U/ml)
2.7
4.9
11.1
12.3
0.098
CA 125(U/ml)
18.8
15
21.4
22.8
0.441
Histology
0.166
Squamous
35(61.4)
94(67.6)
8(80.0)
41(75.9)
Adenocarcinoma
21(36.8)
38(27.3)
2(20.0)
11(20.4)
Adeno-squamous
1(1.8)
7(5)
0(0.0)
2(3.7)
Grade
0.132
1
24(42.1)
20(14.4)
0(0.0)
8(14.8)
2
19(33.3)
77(55.4)
5(50.0)
29(53.7)
3
5(8.8)
32(23.0)
4(40.0)
13(24.1)
Unknown
9(15.8)
10(7.2)
1(10.0)
4(7.4)
Biopsy type
<0.0001
Punch biopsy
21(36.8)
106(76.3)
8(80.0)
41(77.4)
LEEP
36(63.2)
33(23.7)
2(20.0)
12(22.6)
Clinical FIGO tumor stage
<0.0001
IA
15(26.3)
0(0.0)
0(0.0)
0(0.0)
IB1
42(73.7)
102(73.4)
4(40.0)
20(37.0)
IB2
0(0.0)
23(16.5)
3(30.0)
26(48.1)
IIA1
0(0.0)
6(4.3)
2(20.0)
4(7.4)
IIA2
0(0.0)
8(5.8)
1(10.0)
4(7.4)
RH T category (final pathologic_stage )
<0.0001
T1a
15(26.3)
0(0.0)
0(0.0)
0(0.0)
T0b1
16(28.1)
3(2.2)
0(0.0)
0(0.0)
T1b1
26(45.6)
96(66.9)
6(60.0)
11(20.4)
T1b2
0(0.0)
25(18.0)
1(10.0)
11(20.4)
T2a1
0(0.0)
1(0.7)
0(0.0)
3(5.6)
T2a2
0(0.0)
1(0.7)
1(10.0)
0(0.0)
T2b
0(0.0)
16(11.5)
2(20.0)
29(53.7)
Pathologic Tumor size
0.601
2.93
4.24
4.68
<0.0001
Pathologic tumor size
<0.0001
0-≤1
43(75.4)
19(13.7)
0(0.0)
0(0.0)
1-≤2
10(17.5)
21(15.1)
0(0.0)
2(3.7)
2-≤3
2(3.5)
46(33.1)
2(20.0)
9(16.7)
3-≤4
2(3.5)
21(15.1)
4(40.0)
11(20.4)
4-≤5
0(0.0)
18(12.9)
3(30.0)
14(25.9)
5-≤6
0(0.0)
13(9.4)
0(0.0)
7(13.0)
6-≤7
0(0.0)
1(0.7)
0(0.0)
7(13.0)
>7
0(0.0)
0(0.0)
1(10.0)
4(7.4)
LVSI
<0.0001
Yes
4(7.0)
53(38.1)
7(70.0)
36(66.7)
No
53(93.0)
86(61.9)
3(30.0)
18(33.3)
Pathologic deep stromal invasion
<0.0001
Inner 1/3
48(84.2)
27(19.4)
2(20.0)
0(0.0)
Middle 1/3
6(10.5)
44(31.7)
3(30.0)
2(3.7)
Outer 1/3
3(5.3)
68(48.9)
5(50.0)
52(96.3)
Pathologic parametrial invasion
<0.0001
No
57(100.0)
124(89.2)
8(80.0)
25(46.3)
Yes
0(0.0)
15(10.8)
2(20.0)
29(53.7)
Pathologic parametrial invasion laterality
<0.0001
Negative
57(100.0)
124(89.2)
8(80.0)
22(40.7)
Unilateral
0(0.0)
8(5.8)
1(10.0)
14(25.9)
Bilateral
0(0.0)
7(5.0)
1(10.0)
18(33.3)
Pathologic pelvic LN involvement
<0.0001
Negative
55(96.5)
115(82.7)
6(60.0)
30(55.6)
Positive
2(3.5)
24(17.3)
4(40.0)
24(44.4)
Pathologic para-aortic LN involvement
0.001
Negative
51(89.5)
120(86.3)
9(90.0)
45(83.3)
Positive
0(0.0)
10(7.2)
1(10.0)
8(14.8)
Not done
6(10.5)
9(6.5)
0(0.0)
1(1.9)
Pathological uterine involvement
No
56(98.2)
125(89.9)
8(80.0)
26(48.1)
Yes
1(1.8)
14(10.1)
2(20.0)
28(51.9)
MRI tumor size
0.00
2.89
4.06
4.61
<0.0001
MRI pelvic LN involvement
Negative
57(100.0)
128(92.1)
7(70.0)
36(66.7)
Positive
0(0.0)
11(7.9)
3(30.0)
18(33.3)
MRI para-aortic LN involvement
0.46
Negative
57(100.0)
137(98.6)
10(100.0)
53(98.1)
Positive
0(0.0)
2(1.4)
0(0.0)
1(1.9)
MRI uterine corpus invasion
No
57(100.0)
127(91.4)
8(80.0)
27(50.0)
Yes
0(0.0)
12(8.6)
2(20.0)
27(50.0)
MRI deep stromal invasion
No invasion
57(100.0)
2(1.4)
0(0.0)
0(0.0)
Partial invasion
0(0.0)
79(56.8)
6(60.0)
3(5.6)
Complete invasion
0(0.0)
58(41.7)
4(40.0)
51(94.4)
The data are presented as the number (%) or the mean ± SD. FIGO, International Federation of Gynecology and Obstetrics; RH, radical hysterectomy; LVSI, lymphovascular stromal invasion; LN, lymph node; CA 125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; MRI, magnetic resonance imaging.
